



HOXA1 Is an Antagonist of ER α in Breast Cancer

Magali Belpaire¹, Bruno Ewbank¹, Arnaud Tamini¹, Laure Bridoux¹, Noémie Deneyer¹, Damien Marchese¹, Gipsi Lima-Mendez¹, Jean-François Baurain^{2,3}, Dirk Geerts^{4†} and René Rezsöházy^{1*}

¹ Louvain Institute of Biomolecular Science and Technology (LIBST), UCLouvain, Louvain-la-Neuve, Belgium, ² Pôle d'imagerie moléculaire, radiothérapie et oncologie (MIRO), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Woluwe-Saint-Lambert, Belgium, ³ King Albert II Cancer Institute, Cliniques Universitaires St Luc, Woluwe-Saint-Lambert, Belgium, ⁴ Department of Medical Biology, Amsterdam University Medical Centrum (AMC), University of Amsterdam, Amsterdam, Netherlands

OPEN ACCESS

Edited by:

Andrea Morandi,
University of Florence, Italy

Reviewed by:

Peir-In Liang,
Kaohsiung Medical University
Hospital, Taiwan
Alessandro Carrer,
Veneto Institute of Molecular Medicine
(VIMM), Italy

*Correspondence:

René Rezsöházy
rene.rezsöházy@uclouvain.be

†Present address:

Dirk Geerts,
Glycostem Therapeutics, Oss,
Netherlands

Specialty section:

This article was submitted to
Molecular and Cellular Oncology,
a section of the journal
Frontiers in Oncology

Received: 23 September 2020

Accepted: 12 July 2021

Published: 18 August 2021

Citation:

Belpaire M, Ewbank B, Tamini A, Bridoux L, Deneyer N, Marchese D, Lima-Mendez G, Baurain J-F, Geerts D and Rezsöházy R (2021) HOXA1 Is an Antagonist of ER α in Breast Cancer. *Front. Oncol.* 11:609521. doi: 10.3389/fonc.2021.609521

Breast cancer is a heterogeneous disease and the leading cause of female cancer mortality worldwide. About 70% of breast cancers express ER α . HOX proteins are master regulators of embryo development which have emerged as being important players in oncogenesis. HOXA1 is one of them. Here, we present bioinformatic analyses of genome-wide mRNA expression profiles available in large public datasets of human breast cancer samples. We reveal an extremely strong opposite correlation between HOXA1 versus ER expression and that of 2,486 genes, thereby supporting a functional antagonism between HOXA1 and ER α . We also demonstrate *in vitro* that HOXA1 can inhibit ER α activity. This inhibition is at least bimodal, requiring an intact HOXA1 DNA-binding homeodomain and involving the DNA-binding independent capacity of HOXA1 to activate NF- κ B. We provide evidence that the HOXA1-PBX interaction known to be critical for the transcriptional activity of HOXA1 is not involved in the ER α inhibition. Finally, we reveal that HOXA1 and ER α can physically interact but that this interaction is not essential for the HOXA1-mediated inhibition of ER α . Like other HOX oncoproteins interacting with ER α , HOXA1 could be involved in endocrine therapy resistance.

Keywords: HOX proteins, estrogen receptor, NF- κ B, endocrine therapy resistance, PBX

INTRODUCTION

Breast cancer is the most diagnosed female cancer and the leading cause of cancer mortality among women worldwide (1). The four commonly accepted molecular breast cancer subtypes are luminal A, luminal B, HER2-enriched, and basal-like tumors. Three main molecular markers are used to characterize these: ER (estrogen receptor), PR (progesterone receptor), and HER2 (human epithelial growth factor receptor) expression. Luminal A is defined as ER positive (ER+), PR positive (PR+), and HER2 negative (HER2-), and luminal B as ER+, PR+, and HER2-positive (HER2+) or HER2- (2, 3). ER+ cancers show the best prognosis since ER activity, which can drive oncogenesis, can be blocked using selective ER modulators (SERM) like Tamoxifen, aromatase inhibitors, or selective ER downregulators (SERD). However, many tumors develop resistance to such endocrine therapy,

supporting the hypothesis that in addition to ER α expression, an alternative oncoprotein can become involved (4). HER2-enriched breast tumors are HER2+ and ER/PR-. Therapeutic antibodies targeting HER2 can inhibit tumor growth, but often resistance develops to this treatment. Finally, basal-like cancers do not express any of the three markers, ER, PR, and HER2, and are considered to be the most aggressive breast cancers. They are also characterized by cytokeratin 5 and 17 as well as EGFR expression. Basal-like breast cancers are sometimes also grouped as triple-negative breast cancers (TNBCs), but TNBCs do not share all basal-like characteristics (5).

ER α is expressed in about 70% of breast cancers (3). ER α is a transcription factor of the Nuclear Hormone Receptor (NHR) family. It is essential for mammary gland development, notably by mediating the mitogenic action of estrogens. Therefore, deregulation of its expression, abundance, stabilization, or degradation has considerable impacts on cell behavior and can trigger breast cancer development (6–8). ER α contains three well-characterized structural and functional domains: two transcription-activating regions and one DNA-binding domain. The first activating region, AF-1, is a hormone-independent transactivating domain. The second, AF-2, is the ligand-binding domain (LBD) and can regulate AF-1 activity (8).

HOX genes are master regulators of the embryo development. They code for a family of 39 evolutionary extremely well-conserved transcription factors that contain a homeodomain (9). *De novo* HOX gene expression has been reported in a wide variety of cancers, and several HOX genes can function as proper oncogenes (10–13). HOXA1 was notably found to be involved in different types of cancer, including liver (14, 15), stomach (16), lung (17), prostate (18), endometrium (19), and breast cancers (20). HOXA1 *de novo* or overexpression appears systematically associated with cancer progression and poor prognosis. HOXA1 is not expressed in the normal adult mammary gland but has been shown to be upregulated in some breast cancer tissues (20, 21). Experimental data show that HOXA1 overexpression alone is sufficient to promote the oncogenic transformation of mammary epithelial cells (22). In *in vivo* models, Brock and colleagues confirmed the key role of HOXA1 in mammary oncogenesis by demonstrating that silencing HOXA1 with specific siRNAs decreases tumor incidence in mice (23).

At the molecular level, HOXA1 expression can be activated by human growth hormone and E-cadherin. It stimulates cell survival and proliferation by activating p44/42 MAPK- and STAT-mediated gene transcription (22, 24–26). In contrast, HOXA1 inhibition decreases expression of the anti-apoptotic protein BCL2 (20, 27).

We recently addressed the molecular mechanisms of HOXA1 action in breast cancer. We first provided evidence that PBX proteins, which are Three Amino acid Long Extension (TALE-) homeodomain proteins, are crucial HOXA1 cofactors during development (28). Next, we showed that disrupting the HOXA1-PBX interaction severely impairs HOXA1 oncogenic activity (29). This interaction depends on a hexapeptide motif shared by numerous HOX proteins. A WM-to-AA substitution in the hexapeptide indeed abrogated HOXA1's ability to promote

mammary cell proliferation, anchorage-independent cell growth, and contact inhibition loss, as well as its function in activating the expression of target oncogenes like the ephrin receptor gene *EphA2* (29–31).

Second, breast cancer transcriptome analysis highlighted a very strong positive correlation between HOXA1 and NF- κ B pathway gene expression (32). These correlations were reinforced by the identification of several direct HOXA1 interactors that are important NF- κ B pathway modulators (32, 33). At the functional level, Taminiau et al. revealed that HOXA1 can activate the NF- κ B pathway and that this activation is important for cell proliferation and contact inhibition loss, in support of NF- κ B activation as part of HOXA1 oncogenic activity. In addition, it was shown that NF- κ B activation by HOXA1 occurs upstream of NF- κ B nuclear translocation, probably at the level of signaling modulators like TRAF2 and RBCK1, *i.e.*, independent of HOXA1 transcription factor activity (32). NF- κ B proteins are transcription factors involved in cellular processes like inflammation, apoptosis, and cell growth. Their deregulation can cause severe perturbation of cell physiology, and it has been widely accepted that NF- κ B deregulation can trigger cancer (34, 35). Together, our previous reports clearly indicate that molecular mode of HOXA1 oncogenic activity is at least bi-modal since it requires the interaction with PBX or with NF- κ B modulators.

In this study, we present additional breast cancer transcriptome analysis identifying an extremely strong, inverse correlation between genes associated with HOXA1 expression and with ER status: genes that are upregulated in the presence of HOXA1 expression appear downregulated upon ER α activation, and *vice versa*. These opposite correlations led to explore the hypothesis that HOXA1 and ER α could display antagonistic activities.

MATERIALS AND METHODS

Bioinformatic Analysis of Public Genome-Wide Breast Cancer mRNA Expression Datasets

Genome-wide mRNA expression profiling datasets of human breast cancer samples in the public domain (n=45) were retrieved from the NCBI Gene Expression Omnibus (GEO¹), EMBL European Bioinformatics Institute (EMBL-EBI²), or NIH-TCGA³ websites on December 31, 2018. Datasets with <100 tumor samples (n=19) were excluded. Of 26 unique datasets remaining, 14 were excluded because of incomplete clinical annotation or because only specific breast cancer subtypes were included (n=11 and n=3, respectively, for details see **Supplemental Table 1**). These final 12 datasets were analyzed using R2: a genomic analysis and visualization platform⁴ developed in the Department of Oncogenomics at the Amsterdam University Medical Centre–University of Amsterdam, Netherlands,

¹ <https://www.ncbi.nlm.nih.gov/geo/>

² <https://www.ebi.ac.uk/>

³ <https://portal.gdc.cancer.gov/>

⁴ <http://r2.amc.nl>

as described in (36). In addition, for **Figure 2**, the Bergh-159 dataset (GSE1456) was analyzed. The TranscriptView genomic analysis and visualization tool within R2 was used to check if probe-sets uniquely mapped in an antisense orientation to an exon of their target gene⁵. All probe-sets in this study meet these criteria. All expression values and other details of the datasets can be obtained through their GSE, E, or TCGA number from the NCBI-GEO, EMBL-EBI, and NIH-TCGA websites, respectively.

The results of the correlation between *ESR1* and *HOXA1* respective expression profiles and the rest of the breast cancer transcriptomes were split in two lists named *HOXA1+/ESR1-* and *HOXA1-/ESR1+*, which hold, respectively, the genes whose expression profiles correlated positively with the expression of *HOXA1* and negatively with the expression of *ESR1* and the list of those that correlated negatively with *HOXA1* and positively with *ESR1*. We performed functional enrichment analyses on those lists using the <http://geneontology.org/> interface, using Fisher's exact test and corrected for multiple testing following the FDR method. The reference functions were Gene Ontology (GO) molecular function, GO biological process, and GO cellular component.

To assess the relation between *HOXA1* and *ESR1* expression values and survival, we generated Kaplan–Meier plots using the R2 interface. We used the Kaplan Scan feature to split the samples according to the level of expression of *HOXA1* and *ESR1*, respectively, resulting in one split of samples assigned to either high or low *HOXA1* expression and a second split corresponding to either high or low *ESR1* expression. The Kaplan Scan feature establishes the optimum survival cut-off based on a logrank test as described in (37). To reveal the effect of the combination of the expression of *ESR1* and *HOXA1* in survival probability, we performed Kaplan–Meier analysis combining the groups resulted from the Kaplan scan into the four possible combinations of high and low values of expression of *HOXA1* and *ESR1* expression (R2 Kaplan by combination of two categorical tracks).

Plasmid Constructs

Reporter plasmids as well as PREP1, PBX1A, HOXA1, and IκB super repressor (IκB-SR) expression vectors have been previously described (**Table 1**).

The pSG5-hERα expression vector and the 3xERE::luc-TATA reporter vector (hereafter called *ERE::luc*), which includes the estrogen response element of the vitellogenin A2 gene promoter, were kind gifts from Han Weidong (Chinese PLA General Hospital, Beijing, China).

pENTR-ESR1 was obtained from the ORFeome v5.1⁶, thanks to Jean-Claude Twizere (Molecular Biology of Diseases, GIGA, ULiège, Belgium). The expression vectors pEXP-Flag(Nter)-ESR1, pEXP-GST(Nter)-ESR1, and pEXP-VN173(Nter)-ESR1 were generated by Gateway[®] technology (Invitrogen, Carlsbad, USA), with an LR clonase[®] reaction between pENTR-ESR1 and pDEST-Flag(Nter), pDEST-GST(Nter), or pDEST-VN173(Nter), respectively. Similarly, pENTR-ESR1^{AB}, pENTR-ESR1^{CDEF}, and pENTR-ESR1^{EF} were generated by BP clonase[®] reaction between pDONR223 and PCR products obtained from

TABLE 1 | Previously described expression vectors and reporter plasmids.

Plasmids	References
pML-EPHA2-r4-Luc (short name: <i>EphA2::luc</i>)	(30)
pGL4.32[luc2P/NF-κB-RE/Hygro] (short name: <i>NF-κB/luc</i>)	(Promega)
pCMV-LacZ (short name: <i>CMV::lacZ</i>)	(38)
pCS2-PREP1	(39)
pCMV-PBX1A	(40)
IκB super repressor (short name IκB-SR)	(41)
pEXP-Flag(Nter)-mHOXA1	(33)
pEXP-GST(Nter)-mHOXA1	
pEXP-VC155(Nter)-mHOXA1	
pEXP-Flag(Nter)-mHOXA1 ^{Δ71-199}	(42)
pEXP-Flag(Nter)-mHOXA1 ^{ΔHD}	
pEXP-Flag(Nter)-mHOXA1 ^{WM-AA}	
pEXP-Flag(Nter)-mHOXA1 ^{WFQN-SVAA}	
pEXP-GST(Nter)-mHOXA1 ^{Δ71-199}	
pEXP-GST(Nter)-mHOXA1 ^{ΔHD}	
pEXP-GST(Nter)-mHOXA1 ^{WM-AA}	
pEXP-GST(Nter)-mHOXA1 ^{WFQN-SVAA}	
pEXP-VC155(Nter)-mHOXA1 ^{Δ71-199}	
pEXP-VC155(Nter)-mHOXA1 ^{ΔHD}	
pEXP-VC155(Nter)-mHOXA1 ^{WM-AA}	
pEXP-VC155(Nter)-mHOXA1 ^{WFQN-SVAA}	

pGEX2TK-ESR1^{AB}, pGEX2TK-ESR1^{CDEF}, and pGEX2TK-ESR1^{EF} (43), respectively. These three plasmids were kind gifts from Sylvie Mader (Molecular Targeting in Breast Cancer Treatment Research Unit, Université de Montréal, Montréal, Canada). The attB-flanked PCR products were obtained with the following primers (**Table 2**): (1) and (2) for *ESR1*^{AB}; (3) and (4) for *ESR1*^{CDEF}; (5) and (6) for *ESR1*^{EF}. LR clonase[®] reactions were then performed with pDEST-VN173(Nter) to obtain the three corresponding pEXP vectors.

Similarly, pEXP-Flag(Nter)-hHOXA1 and pEXP-VC155(Nter)-hHOXA1 were generated from the pENTR-hHOXA1 from the ORFeome and from the pDEST-Flag(Nter) and pDEST-VC155(Nter), thanks to the Gateway[®] technology (Invitrogen).

Cell Culture and Transfection

The MCF10A, MCF7, HEK293T, and COS7 cell lines were maintained and transfected as described in (32).

Western Blotting

Seven hundred thousand HEK293T cells were seeded per well of six-well plates and transfected with combinations of plasmids encoding Flag- or GST-tagged proteins. Twenty-four hours after transfection, cells were rinsed once with PBS and then lysed in cold IPLS buffer (20 mM Tris-HCl pH7.5, 120 mM NaCl, 0.5

TABLE 2 | Primers used to generate deletion derivatives of the *ESR1* gene.

Primer #	Sequences
(1)	GGGGACAACCTTTGTACAAAAAGTTGGCaccctccaccaccaagcatctgg
(2)	GGGGACAACCTTTGTACAAAAAGTTGGGTAgtagcagtgctctctggcagattcc
(3)	GGGGACAACCTTTGTACAAAAAGTTGGCctgtcagtgctgcaatgactatgc
(4)	GGGGACAACCTTTGTACAAAAAGTTGGGTAtcagaccgtggcagggaacc
(5)	GGGGACAACCTTTGTACAAAAAGTTGGCccagagagatgatggggagggc
(6)	GGGGACAACCTTTGTACAAAAAGTTGGGTAtcagaccgtggcagggaacc

⁵<http://r2.amc.nl> > genome browser

⁶<http://horfdb.dfci.harvard.edu/hv5/>

mM EDTA, 0.5% NP40, 10% glycerol) supplemented with 1× cComplete™ protease inhibitor cocktail (#11697498001, Merck, Darmstadt, Germany), during 20 min on ice under gentle agitation. Cell lysates were centrifuged 5 min at 16,000 g and 4°C, sonicated for 15 s, and then boiled at 95°C for 5 min. Expression of Flag- or GST-fused proteins and ACTIN was analyzed by Western-blotting with primary mouse anti-Flag (#F1804, Merck), or anti-GST antibody (#G1160, Merck) or anti-ACTIN antibody (#A3854, Merck), respectively, and HRP-coupled secondary anti-mouse IgG (#sc-516102, Santa Cruz Biotechnology). Primary Flag- or GST-antibodies were diluted 1:5,000 in 10% milk in TTBS, anti-ACTIN was diluted 1/20,000 in TTBS, and the secondary anti-mouse IgG antibody was diluted 1/10,000 in 1% milk in TTBS. The ACTIN signal was used as a protein loading control.

Glutathione Co-Precipitation

Seven hundred thousand HEK293T cells were seeded per well of a six-well plate and transfected with combinations of plasmids encoding Flag- or GST-tagged proteins. Empty pDEST-GST (Nter) vector was used as a negative control. Proteins were harvested 48 h post-transfection as described above, but without sonication. Thirty μ l of glutathione-sepharose beads (#GE17-0756-01, Sigma-Aldrich, St. Louis, USA) were washed three times with cold IPLS and then added to protein lysates overnight at 4°C on a rotating wheel. Beads were then washed three times with cold IPLS. The first wash was stored to assess the abundance of unbound GST-fusion protein. The beads were then resuspended in Laemmli loading buffer and boiled for 5 min at 95°C. Expression of Flag- or GST-fused proteins was detected as described above. Detection of the Flag epitope reveals the presence or absence of an interaction between the two proteins tested. Detection of the GST tag allows evaluating the abundance of bead-bound GST-protein.

Bimolecular Fluorescence Complementation

Seventy-five thousand COS7 cells were seeded on glass coverslips in 24-well plates and were transfected 16 h growth later with 250 ng of pEXP-VC155(Nter) and 250 ng of pEXP-VN173(Nter) plasmids encoding HOXA1 and ER α fusion proteins, respectively. Empty pDEST-VC155(Nter) and pDEST-VN173 (Nter) vectors were used as negative controls. Twenty-four hours post-transfection, cells were washed twice with PBS and fixed for 20 min with 4% PFA-PBS (#441244, Sigma-Aldrich) at room temperature. Cells were then rinsed twice for 5 min in TBS-T buffer (50 mM Tris-HCl, pH 7.5, 155 mM NaCl, 0.1% Triton X-100 (#10789704001, Merck)) and once for 10 min with TB buffer (50 mM Tris-HCl, pH 7.5). Cells on coverslips were stained in a mounting medium containing DAPI and Vectashield (#H-1200, Labconsult, Brussels, Belgium), and pictures were taken under an epifluorescence microscope (Axioskop 2, Zeiss, Oberkochen, Germany). Fluorescence was quantified with the IMAGEJ software and tested interactions were considered as positive when the emitted fluorescence was at least three times higher than in the negative control conditions. pEXP-VN173(Nter)-

hHOXA1 with pEXP-VC155(Nter)-mHOXA1 was used as a positive BiFC control in each experiment.

Reporter Assays

Two hundred thousand MCF10A cells per well were plated on 24-well plates and transfected with the following plasmids: 250 ng of luciferase reporter plasmid (*ERE::luc* or *EphA2::luc* or *NF- κ B::luc*), 50 ng of *CMV::lacZ*, 250 ng of pEXP-Flag(Nter)-hHOXA1, and/or 100 ng of pCS2-Prep1 and 100 ng of pCMV-Pbx1a, and/or 250 ng of pSG5-hER α and/or 250 ng of I κ B-SR expression vectors, for a total of 1 μ g of DNA per well. For assays involving mHOXA1 deletion variants, 250 ng of *ERE::luc* and 50 ng of *CMV::LacZ* reporter plasmids were transfected together with 250 ng of pSG5-hER α and/or 250 ng of pEXP-Flag(Nter)-mHOXA1, -mHOXA1 ^{Δ H₁D}, ^{Δ Center}, ^{WM-AA}, or ^{WFQN-SVAA} expression vectors. The total amount of DNA was kept equal for all conditions by the addition of carrier pCAT vector when required. Each condition was tested in duplicate, and each experiment was carried out at least three times. Twenty-six hours post-transfection, cells were harvested. Luciferase and β -galactosidase activities were measured with a high-sensitivity Luciferase (#11669893001, Roche, Penzberg, Germany) and a chemiluminescent β -galactosidase assay (#11758241001, Roche), respectively, following the manufacturer's instructions. Luciferase activity was normalized using constitutive β -galactosidase activity. Experiments with HOXA1 variants were conducted using the Dual-Light™ Luciferase & β -Galactosidase Reporter Gene Assay System (#T1003, Thermo Fisher Scientific, Waltham, USA) according to the manufacturer's instructions, except that cell extracts were obtained by collecting cells in 100 μ l lysis buffer.

Statistical Analysis

For the bio-informatic analyses in **Figures 1, 2, Table 3**, and **Supplemental Tables 1–3**, *HOXA1* mRNA expression was correlated to mRNA expression of other genes using a 2 log Pearson test. The significance of a correlation is determined by $t = R/\sqrt{(1-r^2)/(n-2)}$ where R is the correlation value and n is the number of samples. Distribution measure is approximately as t with n-2 degrees of freedom (see ⁷ for details). *HOXA1* mRNA expression correlations with breast cancer clinical parameters in **Table 3** and **Figure 1** were determined using the non-parametric Kruskal-Wallis test. For all tests, differences were considered significant if $p < 0.05$.

The *in vitro* data were analyzed using mixed models in R (lmer function of the lmerTest R package) (44) and SAS 9.4. (mixed procedure). A log-transformation is applied on the response variable to meet the mixed model assumptions (normality and homogeneity of the residuals). Significant differences between groups were analyzed using *post-hoc* comparison tests with Bonferroni correction to ensure the level alpha (= 0.05) in a multiple comparison test setting (45) or through a Tukey test.

⁷<http://vassarstats.net/rsig.html>




FIGURE 1 | High *HOXA1* mRNA expression correlates with the basal breast cancer subtype. *HOXA1* mRNA expression correlation with breast cancer molecular subtypes. Panels (A–D) represent the results from all 4 breast cancer datasets in the public domain with sample number > 100, and annotation on molecular subtype: Bergh-159, Bertucci-266, Booser-508, and Chin-124, respectively. Below the graphs are the different subtypes: basal-like (basal), HER2-overexpressing (Her2), Luminal-A (Lum-A), and Luminal-B (Lum-B), between brackets are the number of samples per subtype. mRNA expression values for the individual samples are presented as open circles, horizontal bars represent (from up to down: maximum value, [upper quartile, median value, lower quartile – boxed], and minimal value. Outlier samples (more or less than 3/2 of upper or lower quartile, respectively) are denoted by “x”. * denotes significant difference with the basal subtype expression ($p < 0.05$, Welch’s ANOVA with post-hoc test, significant differences found for both normal and 2log-transformed expression values).

RESULTS

Bioinformatic Analysis of Public Genome-Wide Breast Cancer mRNA Expression Datasets

We previously identified a causal role between *HOXA1* expression and NF- κ B pathway activation in breast cancer (32). To further explore an oncogenic role for *HOXA1* in breast cancer, we examined *HOXA1* mRNA expression in public genome-wide mRNA expression datasets of human breast cancer samples (Table 3). We analyzed whether *HOXA1* expression levels were correlated to the three main breast cancer molecular markers: ER, PR, and HER2. *HOXA1* mRNA expression showed significant inverse correlation to ER status and PR status of breast cancer samples, in 11 of 12 datasets. Also, PR status shows this opposite correlation with *HOXA1*, in seven of nine datasets with PR status annotation. *HOXA1* expression was not significantly correlated to HER2 tumor status in any of the datasets. These results strongly suggest that ER α and PR tumor expression, and thereby the potential for ER α or PR pathway activation, is decreased in the presence of *HOXA1*.

Interestingly, *HOXA1* expression was significantly correlated to breast cancer molecular subtypes as well. An analysis of the four public datasets annotated for (PAM50) molecular subtypes showed that *HOXA1* was consistently most highly expressed in basal-like samples, compared to HER2 or luminal subtypes, confirming the results in Table 3, and in further support of a role for *HOXA1* in breast cancer aggressiveness (Figure 1 and Supplemental Figure 1).

Since especially the correlation between *HOXA1* mRNA expression and (negative) ER status was significant, in 11 of 12 datasets tested, suggesting that *HOXA1* could repress ER α expression, or vice versa, we wanted to further define the possible signaling pathways involved. To this end, we downloaded all genes whose mRNA expression correlated with *HOXA1* mRNA expression or with tumor ER status (see Table 3). To obtain biologically and statistically robust results, we only included genes that showed significant expression correlation in at least 6 of 12 datasets analyzed, with the extra criterion that the correlations needed to carry the same sign: be positive (e.g., high gene mRNA expression correlates with high *HOXA1* mRNA expression) or negative (e.g., low gene mRNA

expression correlates with high *HOXA1* mRNA expression), with a penalty for conflicting correlations (see *Materials and Methods*). We found 5,878 genes with significant, sign-consistent correlations to ER status in at least six of 12 datasets, and 3,474 genes that correlated to *HOXA1* mRNA expression using the same criteria (**Supplemental Table 2**). Comparison of the two gene lists showed a very large overlap: 2,555 genes were significantly correlated to both *HOXA1* mRNA expression and ER status (**Supplemental Table 3**). Importantly, 2,486 of 2,555 genes (97.30%) showed inverse correlation: opposite correlation to *HOXA1* mRNA expression, but positive correlation to ER status (1,106 genes; 43.29%) or positive correlation to *HOXA1* mRNA expression, but opposite correlation to ER (1,380 genes; 54.01%). Overlap analysis also showed that especially genes oppositely correlated to *HOXA1* mRNA expression but positively to ER expression are enriched, suggesting that *HOXA1* could be involved in the downregulation of these genes and thereby act as an ER α repressor in breast cancer (**Figure 2**). Enrichment analysis of these distinct gene sets showing inverse correlation with *HOXA1* versus ER expression according to Gene Ontology (GO) supports that when *HOXA1* is upregulated while the ER gene *ESR1* is downregulated, tumors show enhanced cytokine and chemokine signaling, as well as enhanced immune response (**Supplemental Table 4**).

To determine to what extent the *HOXA1* versus ER expression status might be clinically relevant, we assessed the effect of *HOXA1* and ER expression on the relapse-free or overall survival probability of patients, and we generated Kaplan-Meier plots with the R2 genomics analysis platform. Out of the 12 datasets used, only four had survival information (**Supplemental Figure 2**). For three datasets, the combined expression status for *HOXA1* and *ESR1* revealed distinct outcomes supportive of a functional interaction between *HOXA1* and ER. Low *HOXA1* associated with high *ESR1* expression is significantly associated to the best survival probability, while high *HOXA1*-low *ESR1* appears as the worst or the second worst condition. Comparing survival curves corresponding to high *ESR1*, expression of *HOXA1* (high or low *HOXA1*) clearly shows an impact. Reciprocally, comparing survival curves corresponding to high *HOXA1*, expression of *ESR1* (high or low *ESR1*) also shows an effect. This supports a functional interaction between *HOXA1* and ER in breast cancer, *ESR1* expression improving the *HOXA1*+ condition, while *HOXA1* expression worsening the survival probability of ER+ patients.

HOXA1 Inhibits ER α Activity Independently of the Cofactors PREP and PBX

To assess the *HOXA1*-ER α functional antagonism suggested by the bio-informatic analyses above, *HOXA1* and ER α activities and their possible interactions were analyzed *in vitro*. *HOXA1* and ER α target gene reporter assays were carried out to establish whether *HOXA1* might interfere with ER α activity, and *vice versa*. Human mammary epithelial cells MCF10A were transfected with plasmids encoding ER α , *HOXA1*, PREP1, and PBX1A and the *ERE::luc* ER activity reporter. This *ERE::luc* reporter contains the gene encoding the luciferase under the control of three ER-binding core sequences




FIGURE 2 | *HOXA1*- and ER status-correlating genes in breast cancer correlate inversely. Overlap between *HOXA1*- and ER status-correlating genes extracted from public genome-wide mRNA expression breast cancer datasets. Venn diagrams represent the large overlap between genes whose mRNA expression correlates with that of *HOXA1*, and with ER status. Top diagram: Of 3474 genes correlated with *HOXA1* expression, the majority, 2486 genes (71.6%), show an inverse correlation with ER status. This is 42.3% of genes correlated with ER status (5878 genes total). Middle diagram: Of 2144 genes positively correlated with *HOXA1* expression, a smaller majority, 1380 genes (64.4%), show an inverse correlation with negative ER status. This is 45.4% of genes oppositely correlated with ER status (3040 genes total). Bottom diagram: Of 1330 genes correlated with *HOXA1* expression, a large majority, 1106 genes (83.2%), show an inverse correlation with positive ER status. This is 39.0% of genes correlated with positive ER status (2838 genes total). The results are in support of an opposite correlation between *HOXA1* mRNA expression and ER status in breast cancer, and suggest that especially genes negatively associated with *HOXA1* mRNA, e.g. genes potentially downregulated by *HOXA1*, are involved in ER status in breast cancer.

TABLE 3 | HOXA1 mRNA expression in breast cancer datasets.

Dataset	ER status		HER2 status		PR status		Correlating genes		Array		Deposition	
	Correlation	P value	ER-/ER+	P value	Correlation	P value	HOXA1	ER status	Platform	Norm.	GSE/EBI	PubMed
Bertucci - 266	Negative	1.19 10 ⁻¹²	113/150	n.s.	Negative	2.69 10 ⁻⁹	7768	9578	Affy U133P2	MAS5.0	21653	20490655
Booser - 508	Negative	3.05 10 ⁻¹⁰	205/297	n.s.	Negative	4.40 10 ⁻⁵	7366	6308	Affy U133A	MAS5.0	25066	21558518
Chin - 124	Negative	0.021	44/80	n.s.	Negative	0.028	2558	5031	Affy U133A	MAS5.0	E-TABM-158	17157792
Clynes - 104 (121)	Negative	0.015	34/67	n.s.	n.d.	n.d.	2685	3971	Affy U133P2	MAS5.0	42568	23740839
EXPO Breast - 351	Negative	0.044	75/150	n.s.	n.s.	n.s.	5204	8808	Affy U133P2	MAS5.0	2109	not yet
Halfwerk - 947	Negative	2.03 10 ⁻⁸	200/581	n.s.	Negative	7.15 10 ⁻⁵	9325	7246	Affy U133A	Complex	several*	several**
Iglehart - 123	Negative	0.038	50/73	n.s.	n.d.	n.d.	2931	9196	Affy U133P2	MAS5.0	5460	18297396
Miller - 251	Negative	6.78 10 ⁻³	34/213	n.d.	Negative	0.030	4047	4635	Affy U133A	MAS5.0	3494	16141321
Prat - 156	n.s.	n.s.	52/104	n.d.	Negative	1.91 10 ⁻³	1155	2184	Affy U133P2	MAS5.0	50948	24443618
TCGA - 1097	Negative	6.18 10 ⁻²⁵	238/808	n.s.	Negative	4.59 10 ⁻¹²	14524	15161	tegars	rsem	BRCA-1098	not yet
TCGA - 528	Negative	2.55 10 ⁻⁴	117/404	n.s.	n.s.	n.s.	7741	12143	AgilentG4502	custom	BRCA-593	23000897
Wang - 286	Negative	8.73 10 ⁻³	77/209	n.d.	n.d.	n.d.	4602	5708	Affy U133A	MAS5.0	2034	15721472

HOXA1 mRNA expression was investigated for correlation to clinical parameters in public genome-wide mRNA expression breast cancer datasets. Data were downloaded and analysed as described in the Materials and Methods. The first column represents name and size of the dataset. Columns 2-4 represent ER tumour status; sign and p value of correlation with HOXA1 mRNA expression, sample numbers with ER- versus ER+ status, respectively. Column 5 represents the correlation between HOXA1 mRNA expression and HER2 tumour status. Columns 6 and 7 represent sign and p value of the correlation between HOXA1 mRNA expression and PR tumour status, respectively. Columns 8 and 9 represent the amount of genes whose expression correlates with HOXA1 mRNA expression and ER tumour status, respectively. Columns 10 and 11 represent array type and data normalization method, respectively. Columns 12 and 13 represent data set deposition: NCI-BE-GENE/EMBL-EBI dataset identifier and PubMed ID, respectively. * Dataset is compiled of GSE1456/3494/5327/6532/7390 and EBI E-TABM-158. ** PubMed ID: 16813654, 29136509, 17420468, 20479250, 25786628, 17157792, respectively. n.d. means no data, n.s. means test result not significant (p > 0.05).

from the vitellogenin A2 gene promoter. As expected, ERα is able to activate *ERE::luc*. HOXA1 alone does not activate *ERE::luc*, but rather decreases the activity of the reporter (Figure 3). In addition, in the presence of HOXA1, *ERE::luc* activation by ERα significantly decreased, demonstrating that HOXA1 can inhibit the transcriptional activity of ERα.

HOXA1 transcriptional activity critically relies on its interaction with PBX proteins (28, 40, 46). Magnani *et al.* uncovered that PBX1 and ERα share a large proportion of their respective target gene promoter-binding sites in MCF7 human mammary cancer cells, and suggested that ERα and PBX could physically interact (47). Since PBX1 is a shared partner between HOXA1 and ERα, we considered that the HOXA1-ERα antagonism could act through competition for PBX1. We therefore tested the effect of PBX1A on HOXA1 and ERα




FIGURE 3 | HOXA1 inhibits ERα activity in presence and in absence of the cofactors, PREP1 and PBX1A. MCF10A cells were transfected with plasmids encoding ERα, Flag-HOXA1 along with *CMV::lacZ* and *EREluc* without (black boxes) or with (grey boxes) PREP1 and PBX1A (PP). ER-mediated luciferase activity (luc) was reported to the β-galactosidase activity (gal) (relative luc/gal activity). The activation of the ER reporter by ERα was reduced in presence of HOXA1 (black) and this effect is also observed in the presence of PREP1 and PBX1A (grey) (N≥3). The relative *EREluc* activity in presence of ERα was set to 1. * means p < 0.05 (N≥3, n=2). Error bars represent standard deviation; for N experiments and n replicates per experiment.

activity. To promote PBX nuclear entry, we also included PREP1 in the assay (48). MCF10A immortalized normal human mammary cells were transfected as described above, with the addition of plasmids encoding PREP1 and PBX1A. Addition of PREP1 and PBX1A significantly increased ER α activation of the *ERE::luc* reporter. However, HOXA1 still inhibited ER α activity, showing that HOXA1 can interfere with the ER α ability to stimulate transcription, both in the presence or the absence of PREP1 and PBX1A (**Figure 3**).

HOXA1 DNA Contact Is Important for ER α Inhibition

To characterize the functional interaction between HOXA1 and ER α , we performed luciferase reporter assays with murine HOXA1 (mHOXA1) mutant variants (mHOXA1 shares 94.7% sequence identity with human HOXA1, hHOXA1). HOXA1 protein contains two histidine repeats, a so-called hexapeptide motif shared by most HOX proteins and a homeodomain, as depicted in **Figure 4A**. The hexapeptide is a six amino acid hydrophobic sequence involved in PBX interaction. The homeodomain is the only DNA-binding domain of HOX proteins (9), but it also contributes to protein-protein interactions (42, 49–51).

The mHOXA1 mutant variants assayed are the following. mHOXA1 ^{Δ H_{HD}} lacks the homeodomain, and mHOXA1^{WFQN-SVAA} displays four amino acid substitutions in the third helix of the homeodomain. These two HOXA1 variants are impaired in their DNA-binding capacity. mHOXA1 ^{Δ 71-199} (hereafter referred to as mHOXA1 ^{Δ Center}) lacks a central region of the protein, extending from amino-acid 71 to 199. mHOXA1^{WM-AA} has a mutant hexapeptide and has lost its capacity to interact with PBX (32, 46, 52, 53). MCF10A cells were transfected with HOXA1 expression plasmids to assess their effect on ER α activity, as determined by *ERE::luc* activity. Like the hHOXA1 protein, mHOXA1 was efficient in inhibiting ER α . mHOXA1 variants with decreased DNA binding did not impair ER α activity, but mHOXA1^{WM-AA} still could (**Figure 4B**). This result corroborates the observation that the HOXA1-mediated ER α inhibition does not rely on PBX, i.e., the ability of HOXA1 to interact with PBX. Next, these results also suggest that the capacity of HOXA1 to bind DNA through its homeodomain is important for the ER α inhibition.

HOXA1 and ER α Can Interact in the Cell Nucleus

After establishing that HOXA1 and ER α can functionally interact, we next addressed whether HOXA1 and ER α also physically interact. We first performed glutathione co-precipitation (CoP) analysis on cell lysates of HEK293T cells transfected with Flag-hHOXA1 and GST-ER α expression vectors, and monitored fusion protein abundance as a measure of HOXA1-ER α interaction by Western-blotting. Co-expression of unfused GST and Flag-hHOXA1 was used as a negative control. As illustrated in **Figure 5A**, Flag-hHOXA1 was retrieved only by precipitating GST-ER α on glutathione beads. This result shows that HOXA1 protein can bind ER α protein.

In addition, Bimolecular Fluorescence Complementation (BiFC) assays were performed as an independent method to

validate HOXA1-ER α protein binding and to establish the intracellular compartment where the interaction occurs. BiFC relies on the complementation between two fragments of the green fluorescent protein Venus (VN173 and VC155). Candidate interactors are fused with VN173 or VC155, and if the proteins of interest interact, VN173 and VC155 reassemble a fluorescent Venus. COS7 cells were transfected with VC155-hHOXA1 and VN173-ER α fusion human proteins. Co-expression of VC155-hHOXA1 with unfused VN173 and reciprocally VN173-ER α with unfused VC155, as well as unfused VN173 and VC155, together were used as negative controls. A three-fold increase in fluorescence signal between test conditions and all three negative controls was applied as a minimal threshold for a valid protein interaction. A significant fluorescence complementation was detected and observed in the nucleus of the cells expressing VC155-HOXA1 and VN173-ER α (**Figure 5B**), thereby confirming HOXA1 and ER α can interact.

The HOXA1 and ER α Interaction Relies on Various Protein Determinants

To identify the determinants of the molecular interaction between HOXA1 and ER α , mHOXA1 variants were tested in protein CoP and BiFC assays. The interaction between the murine HOXA1 wild type and ER α was first confirmed in CoP of GST-mHOXA1 and Flag-ER α (**Figure 6A**). This interaction was not impaired by the deletion of the central part of HOXA1. However, the variant lacking homeodomain (mHOXA1 ^{Δ H_{HD}}) did not show CoP with ER α above background. In addition, the mHOXA1^{WM-AA} and ^{WFQN-SVAA} mutants showed weaker ER α interaction.

Consistent with CoP assays, BiFC analysis confirmed the interaction between mHOXA1 and ER α (**Figure 6B**). mHOXA1 ^{Δ H_{HD}} showed similar complementation fluorescence signal intensity as HOXA1 wild type, but mHOXA1 ^{Δ Center} could no longer bind ER α (**Figures 6B, C**). A decrease in interaction was also observed with both variants with point mutations. The WM to AA mutation negatively impacted the interaction with ER α (**Figures 6B, C**). Within three repetitions, we observed twice loss of interaction with VN173-ER α (**Figure 6B**). Finally, mHOXA1^{WFQN-SVAA} appears slightly impaired in the interaction with ER α -HOXA1 wild type (**Figures 6B, C**).

Although the CoP and BiFC assay results are not completely consistent (see **Table 4**), they both show that HOXA1 hexapeptide and homeodomain point mutations decrease HOXA1-ER α interaction.

Next, ER α variants were analyzed for their ability to bind HOXA1. ER α contains two transactivation domains (called AF) and DNA- and ligand-binding domains (called DBD and LBD, respectively) (8). Along the ER α sequence, six regions can be defined (called A to F, **Figure 7A**). Region A prevents transcription activity in the absence of ER α ligand by binding to the C-terminal end of the protein. Region B contains transactivation domain AF-1. Region C contains two zinc fingers and mediates DNA binding. Region D is a protein hinge. Region E contains a hydrophobic pocket which binds ER α ligands and transactivation domain AF-2. Region F is involved in 14-3-3 protein interactions. BiFC assays (**Figure 7B**) show that only




FIGURE 4 | Map of HOXA1 variants and their impact on ER α activity. **(A)** hHOXA1 WT (336 amino acids) encompasses two histidines stretches of ten (10H) and five amino acids (5H), a hexapeptide (HP) and a homeodomain (HD) of sixty amino acids structured in three α -helices. mHOXA1 WT (331 amino acids) shares 94,7% identity with hHOXA1 WT. A major difference is the length of the first histidine tract showing eleven amino acids in the mouse. mHOXA1 ^{Δ HD} is deprived of the homeodomain, responsible for the loss of DNA binding. mHOXA1 ^{Δ Center} lacks the 129-amino acid sequence between the first histidine repeat and the hexapeptide. mHOXA1^{WM-AA} shows a mutation in the sequence of the hexapeptide, perfectly conserved between the human and mouse proteins and changed from TFDWMK to TFDAAK, which implies the loss of PBX interaction. mHOXA1^{WFQN-SVAA} harbours a mutation in the third α -helix of the homeodomain, which impairs DNA binding. **(B)** Impact of HOXA1-derivatives on the ER α transcriptional activity. MCF10A cells were transfected with plasmids encoding ERE_{luc}, ER α , Flag-hHOXA1, Flag-mHOXA1 WT, Flag-mHOXA1 ^{Δ HD}, Flag-mHOXA1 ^{Δ Center}, Flag-mHOXA1^{WM-AA}, Flag-mHOXA1^{WFQN-SVAA} and β -galactosidase under the control of a CMV promoter. ER-mediated luciferase activity (luc) was reported to the β -galactosidase activity (gal). Activation of the ER reporter by ER α is reduced in the presence of Flag-hHOXA1 and Flag-mHOXA1 WT. This effect is lost with the deletion or the mutation of the homeodomain, as well as upon the deletion of the central part of the protein. Mutations in the hexapeptide does not affect the ability of HOXA1 to inhibit ER α (N=3, n=2). n.s. means test result not significant ($p > 0.05$), *** means $p < 0,001$. Error bars represent standard deviation, for N experiments and n replicates per experiment.

ER α ^{CDEF} failed to interact with HOXA1. Both ER α ^{AB} and ER α ^{EF} showed a slightly increased HOXA1 binding compared to wild type ER α . These data support that CD might impair HOXA1 binding by EF, in the absence of AB.

HOXA1-Mediated ER α Inhibition Involves Its Ability to Activate the NF- κ B Pathway

We previously demonstrated that HOXA1 can activate NF- κ B upstream of the I κ B inhibitor, probably through the interaction of signaling pathway modulators TRAF2 and RBCK1 (32). In the literature, a large number of positive and negative cross-talks have been identified between the ER α and NF- κ B signaling pathways. Many such reports showed that NF- κ B and ER α can exert antagonistic activities (54–56). We therefore investigated whether NF- κ B could play a role in the HOXA1-ER α antagonism. MCF10A cells were transfected with plasmids encoding Flag-HOXA1 and ER α , together with the CMV::lacZ and ERE::luc reporter plasmids. Also added was a dominant negative I κ B α derivative (I κ B α S32/36A, hereafter called I κ B-super repressor, or I κ B-SR). I κ B-SR cannot be phosphorylated by the IKK complex and subsequently degraded. Its interaction with p65/p50 heterodimers inhibits their translocation into the nucleus and impairs NF- κ B pathway activity (57, 58).

As already observed, HOXA1 impaired ER α activity on its target reporter (Figure 8, compare conditions 4 and 6). Addition

of I κ B-SR had distinct effects on the outcome of the assay. On the one hand, inhibiting NF- κ B activity by I κ B-SR tends to stimulate ER α (Figure 8, compare conditions 4 and 7). On the other hand, I κ B-SR significantly diminished the inhibitory effect exerted by HOXA1 on ER α (Figure 8, compare conditions 6 and 8). Inversely, HOXA1 was able to antagonize the ER α stimulation provided by I κ B-SR. The HOXA1 effects occurred both in the presence and in the absence of the PREP1 and PBX1A, suggesting that HOXA1-mediated inhibition and its release by I κ B-SR take place independently of these cofactors known to be critically involved in the HOXA1 transcriptional activity. These data together show that the NF- κ B inhibition and HOXA1 expression have opposite effects on ER α , as well as that the NF- κ B pathway and HOXA1 functionally interact in inhibiting ER α activity. This supports that the HOXA1-mediated activation of NF- κ B is involved in the ER α inhibition.

ER α Does Not Inhibit HOXA1 Transcription Activity

Upon demonstrating that HOXA1 can inhibit ER α activity we wanted to test the opposite: the influence of ER α on HOXA1 activation of its known direct target, *EphA2* (30). *EphA2* was shown to be upregulated in TNBC whereas estrogens downregulate it in ER+ breast cancer (59, 60) (reviewed in (61)). MCF10A cells were transfected with plasmids encoding




FIGURE 5 | Interaction between human HOXA1 and ER α in co-precipitation and BiFC assays. **(A)** For co-precipitation assays, HEK293T cells were transfected with plasmids encoding Flag-HOXA1 and GST or GST-ER α . Protein abundance was monitored prior to co-precipitation with anti-Flag and anti-GST antibodies (Input). β -actin was used as a loading control. After co-precipitation (CoP), Flag-HOXA1 is retrieved by precipitating GST-ER α on glutathione beads, while not with GST alone (N=6, n=1). **(B)** For BiFC assays, COS7 cells were transfected with plasmids encoding human HOXA1 and ER α respectively fused with VC155 and VN173. Unfused VC155 and VN173 were used for negative controls. BiFC signal is observed when VC155-HOXA1 and VN173-ER α are transfected together, while not in negative controls. The insert shows that the BiFC signal provided by the VC155-HOXA1 and VN173-ER α interaction is nuclear (N=4, n=1). Scale bars represent 200 μ m; N, number of experiments; n, number of replicates per experiment.

Flag-HOXA1, PREP1, and PBX1A, and ER α , together with the *EphA2::luc* reporter plasmid. As expected, HOXA1 together with the TALE cofactors, PREP1 and PBX1A, provided a significant *EphA2::luc* activation (**Figure 9A**). However, this activation was not significantly changed by the presence of ER α . Therefore, in our *in vitro* assays, HOXA1 transcription activity does not appear to be modified by ER α .

ER α Does Not Inhibit HOXA1-Mediated NF- κ B Activation

Finally, we addressed whether ER α could interfere with HOXA1-mediated NF- κ B activation. MCF10A cells were transfected with

Flag-HOXA1 and ER α expression plasmids, together with an NF- κ B reporter plasmid. Again, activity assays revealed that ER α did not significantly inhibit NF- κ B::*luc* activation by HOXA1 (**Figure 9B**). Therefore, ER α also does not seem to inhibit the non-transcriptional NF- κ B-activation by HOXA1.

DISCUSSION

Bioinformatic analysis of genome-wide mRNA expression in large public datasets of human breast cancer samples pointed out that *HOXA1* mRNA expression is higher in basal-like breast cancer




FIGURE 6 | Mapping of HOXA1 regions involved in the HOXA1-ER α interaction. **(A)** For co-precipitation, HEK293T cells were transfected with plasmids encoding Flag-ER α and GST, GST-mHOXA1 WT, GST-mHOXA1 Δ HD, GST-mHOXA1 Δ Center, GST-mHOXA1^{WM-AA} and GST-mHOXA1^{WFQN-SVAA}, respectively. GST-mHOXA1 WT interacts with Flag-ER α and the deletion of the central part of HOXA1 does not affect the interaction (N>3). GST-mHOXA1 Δ HD loses the interaction with Flag-ER α (N>3). GST-mHOXA1^{WM-AA} and ^{WFQN-SVAA} show weaker interaction with Flag-ER α (N=3/5). **(B)** For BiFC, COS7 cells were transfected with plasmids encoding VN173-ER α and VC155-mHOXA1 WT, VC155-mHOXA1 Δ Center, VC155-mHOXA1 Δ HD, VC155-mHOXA1^{WM-AA} and VC155-mHOXA1^{WFQN-SVAA}, respectively. VC155-mHOXA1 interacts with VN173-ER α . VC155-mHOXA1 Δ HD interacts with VN173-ER α similarly to the wild type. VC155-mHOXA1 Δ Center, VC155-mHOXA1^{WM-AA} and VC155-mHOXA1^{WFQN-SVAA} display weaker BiFC signal than the wild type VC155-mHOXA1 (N=3, n=2). Scale bars represent 200 μ m; N, number of experiments; n, number of replicates per experiment. **(C)** BiFC quantification. Fluorescence ratios between the tested condition and the negative control pDest VN173 + VC155-mHOXA1 (CTRL1); the tested condition and the negative control pDest VN173-ER α + pDest VC155 (CTRL2); the tested condition and the negative control pDest VN173 + pDest VC155 (CTRL3). A three-fold increase in fluorescence signal between negative controls and tested conditions was applied as a minimal threshold to conclude for an interaction. Grey boxes indicate where the threshold of >3 is not reached.

subtype compared to HER2-enriched, luminal A, and luminal B subtypes. This supports the contribution of HOXA1 in cancer aggressiveness and thereby reinforces its critical role in breast oncogenesis. Bioinformatics also allowed us to reveal an extremely strong, opposite correlation between the HOXA1 mRNA expression and ER status. We identified 2,555 genes whose expression were supportive of a functional antagonism between

HOXA1 and ER α . From this starting observation, we confirmed *in vitro* that (1) HOXA1 can inhibit ER α activity. We further demonstrated (2) that this inhibition requires an intact HOXA1 DNA-binding homeodomain and involves its DNA-binding independent capacity to activate NF- κ B (32). The HOXA1 action towards ER α is therefore bimodal. We also showed (3) that ER α inhibition does not require HOXA1-PBX interaction.


TABLE 4 | Comparative table for CoP and BiFC interaction assays.


Interaction between ER α and mHOXA1 variants	CoP	BiFC
mHOXA1 ^{WT}	+	+
mHOXA1 ^{ΔH_D}	-	+
mHOXA1 ^{ΔC_{enter}}	+	+/-
mHOXA1 ^{WM-AA}	+/-	+/-
mHOXA1 ^{WFQN-SVAA}	+/-	+/-

+, positive interaction (by reference to the mHOXA1^{WT} protein); +/-, decreased interaction; -, lost interaction.

Finally, we provided evidence (4) that HOXA1 and ER α can physically interact in the cell nucleus and that this protein binding relies on various protein determinants but would not be essential for HOXA1 inhibition of ER α transcription activity.


According to our *in vitro* data, HOXA1 can inhibit ER α activity, but ER α cannot repress HOXA1 function. Bioinformatic analysis showed that, among the 2,555 genes shared by the HOXA1 and ER α -associated mRNA expression profiles, about half is upregulated in the presence of HOXA1 but downregulated in ER⁺ cancers, while the other half shows the opposite correlation. One straightforward scenario would be that HOXA1 can impair ER α activity on both its positively and negatively regulated target genes. HOXA1 expression has been shown to be strongly correlated to poor prognosis in breast cancer (20). The inhibition HOXA1 exerts on ER α can define one modality of HOXA1 action resulting in cancer aggressiveness. HOXA1 activity would result in conferring gene expression profiles and cell properties similar to ER-





cancers. Consistently, low expression levels of microRNAs targeting *HOXA1* are also associated with poor prognosis and Tamoxifen resistance (3, 62–66). Therefore, early *de novo* *HOXA1* expression in the mammary gland might lead to the development of aggressive subtypes of breast cancer, and late *HOXA1* expression in an ER+ tumor environment might lead to endocrine therapy resistance.

Importantly, Brock et al. demonstrated that *HOXA1* expression repression with siRNAs leads to a decrease in tumor incidence and an increase of ER expressing cells (23). This supports that *HOXA1* could interfere with the ER status of mammary cancerous cells and thereby influence the outcome of endocrine therapies. Moreover, in support of such a switch in breast cancer driver, from ERα to *HOXA1*, Mahajan et al. have shown that *HOXA1* expression in breast cancer can be induced by ERα and that this could be linked to the acquisition of Tamoxifen resistance. Mahajan et al. indeed established that *HOXA1* expression can be triggered by a complex composed of ACK1, ERα, and KDM3A. Upon exposure to heregulin, activation of the receptor tyrosine kinase HER2 results in the phosphorylation and activation of the ACK1 protein kinase. Activated ACK1 then interacts with ERα and phosphorylates the histone demethylase KDM3A. All three partners, ACK1, KDM3A, and ERα, bind to a target site in the first intron of *HOXA1*. KDM3A then removes H3K9 repressive marks and



induces *HOXA1* transcription, all in the presence of Tamoxifen (67). The authors finally suggest that the ACK1 activation-

HOXA1 expression cascade is involved in ER modulator resistance. In the light of our data, we could therefore propose that after activation by ER α , HOXA1 would exert a negative feedback loop on ER α activity and elicit Tamoxifen resistance.

The HOXA1-mediated inhibition of ER α we highlighted involves the activation of the NF- κ B pathway. We have earlier uncovered the ability of HOXA1 to activate the NF- κ B pathway after finding strong correlations between the mRNA expression of *HOXA1* and players of the NF- κ B signaling network in public datasets of human breast cancer samples (32). Indeed, TNBC was described to have constitutive NF- κ B pathway activation (68), which has been associated with endocrine therapy resistance and poor patient outcome (69–71). In complete agreement with this, NF- κ B has been shown to be able to repress ER α expression. For instance, (1) NF- κ B activates BCL2/RAS signaling and then inhibits *ESR1* expression through the repressor action of the zinc finger protein PRDM1; (2) the serine/threonine kinase PKC θ can both promote NF- κ B activity and inhibit *ESR1* expression; (3) NF- κ B can activate the methyltransferase EZH2, that can suppress *ESR1* transcription, and is thereby associated with poor outcome to Tamoxifen therapy (70, 72–75). Finally, Oida *et al.* demonstrated that Tamoxifen-resistant MCF7 cells expressed less ER α and that ER α expression can be rescued by inhibiting IKK β (76). Instead of being involved in repressing expression, our data indicate that NF- κ B can inhibit the activity of the ER α protein through its activation by HOXA1. Therefore, HOXA1 and NF- κ B could operate a switch in cell growth control by dominating ER α , taking the lead in the oncogenic process and decreasing endocrine therapy sensitivity.

In addition to the functional interaction between HOXA1 and ER α , we also observed that the HOXA1 and ER α proteins can physically bind. This interaction was impaired by the removal of the HOXA1 central part and homeodomain, large protein regions, of 129 and 60 amino acids, respectively. Their deletion could either remove crucial amino acids or disrupt a three-dimensional arrangement involved in protein-protein interaction. Both HOXA1 regions have already been shown to be involved in protein-protein interactions (42, 77). Even more informative are the WM-AA and WFQN-SVAA point mutations, which weakened the interaction with ER α . HOXA1^{WM-AA} is unable to interact with PBX1A and consequently most probably loses its capacity to interact with most or all of its transcriptional targets (46, 52). Mutating WFQN into SVAA removes the conserved glutamine and asparagine of the homeodomain necessary for DNA binding (40). The decreased ER α binding of these HOXA1 mutants, which are also affected in their DNA binding, might indicate that the HOXA1-ER α interaction requires HOXA1 DNA binding. Alternatively, the HOXA1 homeodomain and hexapeptide motif might be directly involved in its docking onto ER α .

All HOXA1 mutants tested in this study are impaired in ER α binding, and three of them also lose the ability to inhibit ER α . HOXA1^{WM-AA} can still inhibit ER α activity despite decreased ER α binding. Therefore, molecular interaction between ER α and HOXA1 might not be necessary to inhibit ER α activity, or slightly impaired binding is not detrimental for HOXA1

functional inhibition of ER α . Alternatively, we cannot exclude that the BiFC and CoP assays might be sensitive enough to detect a loss of molecular interaction, while the luciferase reporter could not be sensitive to a moderate loss of HOXA1-mediated inhibition by the mutant. In any case, the functional significance of the HOXA1-ER α interaction needs further investigation. For example, what needs to be determined is to what extent genes with mRNA expression that is oppositely correlated to HOXA1 and ER α in breast cancer correspond to shared direct target genes, on which the HOXA1-ER α molecular interaction will be translated into a functional transcription output. An important step would be identifying which genes have promoter binding by HOXA1 and/or ER α and determine their regulation. Finally, HOXA1^{WFQN-SVAA} and ^{- Δ Center} variants can activate NF- κ B (32) but cannot inhibit ER α activity (this study). Therefore, a multi-modal mechanism of HOXA1-mediated ER α inhibition might exist for which activation of NF- κ B is involved but not sufficient. Another modality of ER α inhibition might involve HOXA1 DNA-binding capacity. A caveat here is that the loss of inhibition capacity revealed by homeodomain deletion or mutation could be not due to their loss of DNA binding, but rather to HOXA1 structure disruption.

HOXA1 is not the only homeodomain protein that functionally interacts with ER α and is correlated with poor prognosis of breast cancer. HOXB13 downregulates ER α expression and activity. Inversely, HOXB7 associates with ER-binding sites to act as an ER α co-activator. HOXB7 binds ER α *via* its homeodomain, in line with the importance of the homeodomain for the HOXA1-ER α interaction. Nonetheless, our data clearly support that unlike HOXB7, HOXA1 inhibits rather than stimulates ER α activity. Remarkably, although their functional interactions with ER α clearly differ, the activities of these three HOX proteins, HOXA1, HOXB7, and HOXB13, have been linked to Tamoxifen resistance and poor prognosis of breast cancer (51, 78–80), most probably reflecting roles in different cancer cell processes, possibly at different stages of tumor development.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study and referred to, with identifiers, in **Table 3** and **Supplemental Table 1**.

AUTHOR CONTRIBUTIONS

MB: Conceptualization, investigation, and writing original draft. BE: Investigation. AT: Investigation. LB: Resources. ND: Resources. DM: Resources. J-FB: Funding acquisition and supervision. DG: Conceptualization, investigation, writing original draft, and writing reviewing and editing. RR: Funding acquisition, supervision, project administration, conceptualization, writing reviewing and editing. All authors contributed to the article and approved the submitted version.

FUNDING

MB is a Fonds National de la Recherche Scientifique - FNRS - Télévie grant holder. This work was supported by the Fonds de la Recherche Scientifique -FNRS under Grants n°7.4555.16 and 7.6513.18 and the Fonds Spéciaux de Recherche from UCLouvain.

ACKNOWLEDGMENTS

We thank Han Weidong (Chinese PLA General Hospital, Beijing, China) for the pSG5-hER α expression vector and the 3xERE::luc-TATA reporter vector, Jean-Claude Twizere (Molecular Biology of Diseases, GIGA, ULiège, Belgium) for the pENTR-ESR1, and Sylvie Mader (Molecular Targeting in

Breast Cancer Treatment Research Unit, Université de Montréal, Montréal, Canada) for the pGEX2TK-ESR1^{AB}, pGEX2TK-ESR1^{CDEF}, and pGEX2TK-ESR1^{EF}. We also thank Catherine Rasse and Vincent Bremhost (SMCS, UCLouvain, Belgium) for the statistical analyses. Our gratitude goes to Jan Koster and Richard Volckmann for their help in working with the R2 genomics platform. The authors would like to thank Anneke Strietman for her courage and inspiration.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fonc.2021.609521/full#supplementary-material>

REFERENCES

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* (2018) 68(6):394–424. doi: 10.3322/caac.21492
- Tang Y, Wang Y, Kiani MF, Wang B. Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer. *Clin Breast Cancer* (2016) 16(5):335–43. doi: 10.1016/j.clbc.2016.05.012
- Amorim M, Lobo J, Fontes-Sousa M, Estevo-Pereira H, Salta S, Lopes P, et al. Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer. *Front Genet* (2019) 10:815. doi: 10.3389/fgene.2019.00815
- Szostakowska M, Trebanska-Stryjewska A, Grzybowska EA, Fabisiewicz A. Resistance to Endocrine Therapy in Breast Cancer: Molecular Mechanisms and Future Goals. *Breast Cancer Res Treat* (2019) 173(3):489–97. doi: 10.1007/s10549-018-5023-4
- Rakha EA, Ellis IO. Triple-Negative/Basal-Like Breast Cancer: Review. *Pathology* (2009) 41(1):40–7. doi: 10.1080/00313020802563510
- Anderson E, Clarke RB. Steroid Receptors and Cell Cycle in Normal Mammary Epithelium. *J Mammary Gland Biol Neoplasia* (2004) 9(1):3–13. doi: 10.1023/B:JOMG.0000023584.01750.16
- Kulkoyluoglu E, Madak-Erdogan Z. Nuclear and Extranuclear-Initiated Estrogen Receptor Signaling Crosstalk and Endocrine Resistance in Breast Cancer. *Steroids* (2016) 114:41–7. doi: 10.1016/j.steroids.2016.06.007
- Arnal JF, Lenfant F, Metivier R, Flouriot G, Henrion D, Adlanmerini M, et al. Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications. *Physiol Rev* (2017) 97(3):1045–87. doi: 10.1152/physrev.00024.2016
- Rezsohazy R, Saurin AJ, Maurel-Zaffran C, Graba Y. Cellular and Molecular Insights Into Hox Protein Action. *Development* (2015) 142(7):1212–27. doi: 10.1242/dev.109785
- Abate-Shen C. Deregulated Homeobox Gene Expression in Cancer: Cause or Consequence? *Nat Rev Cancer* (2002) 2(10):777–85. doi: 10.1038/nrc907
- Samuel S, Naora H. Homeobox Gene Expression in Cancer: Insights From Developmental Regulation and Deregulation. *Eur J Cancer* (2005) 41(16):2428–37. doi: 10.1016/j.ejca.2005.08.014
- Shah N, Sukumar S. The Hox Genes and Their Roles in Oncogenesis. *Nat Rev Cancer* (2010) 10(5):361–71. doi: 10.1038/nrc2826
- de Bessa Garcia SA, Araujo M, Pereira T, Mouta J, Freitas R, et al. HOX Genes Function in Breast Cancer Development. *Biochim Biophys Acta Rev Cancer* (2020) 1873:188358. doi: 10.1016/j.bbcan.2020.188358
- Zha TZ, Hu BS, Yu HF, Tan YF, Zhang Y, Zhang K. Overexpression of HOXA1 Correlates With Poor Prognosis in Patients With Hepatocellular Carcinoma. *Tumour Biol* (2012) 33(6):2125–34. doi: 10.1007/s13277-012-0472-6
- Tao C, Sun H, Sang W, Li S. miRNA-99a Inhibits Cell Invasion and Migration in Liver Cancer by Directly Targeting HOXA1. *Oncol Lett* (2019) 17(6):5108–14. doi: 10.3892/ol.2019.10199
- Yuan C, Zhu X, Han Y, Song C, Liu C, Lu S, et al. Elevated HOXA1 Expression Correlates With Accelerated Tumor Cell Proliferation and Poor Prognosis in Gastric Cancer Partly via Cyclin D1. *J Exp Clin Cancer Res* (2016) 35:15. doi: 10.1186/s13046-016-0294-2
- Xiao F, Bai Y, Chen Z, Li Y, Luo L, Huang J, et al. Downregulation of HOXA1 Gene Affects Small Cell Lung Cancer Cell Survival and Chemoresistance Under the Regulation of miR-100. *Eur J Cancer* (2014) 50(8):1541–54. doi: 10.1016/j.ejca.2014.01.024
- Wang H, Liu G, Shen D, Ye H, Huang J, Jiao L. HOXA1 Enhances the Cell Proliferation, Invasion and Metastasis of Prostate Cancer Cells. *Oncol Rep* (2015) 34(3):1203–10. doi: 10.3892/or.2015.4085
- Li X, Pang L, Yang Z, Liu J, Li W, Wang D. LncRNA HOTAIRM1/HOXA1 Axis Promotes Cell Proliferation, Migration and Invasion In Endometrial Cancer. *Oncotargets Ther* (2019) 12:10997–1015. doi: 10.2147/OTT.S222334
- Liu J, Liu J, Lu X. HOXA1 Upregulation is Associated With Poor Prognosis and Tumor Progression in Breast Cancer. *Exp Ther Med* (2019) 17(3):1896–902. doi: 10.3892/etm.2018.7145
- Chariot A, Castronovo V. Detection of HOXA1 Expression in Human Breast Cancer. *Biochem Biophys Res Commun* (1996) 222(2):292–7. doi: 10.1006/bbrc.1996.0737
- Zhang X, Zhu T, Chen Y, Mertani HC, Lee KO, Lobie PE. Human Growth Hormone-Regulated HOXA1 Is a Human Mammary Epithelial Oncogene. *J Biol Chem* (2003) 278(9):7580–90. doi: 10.1074/jbc.M212050200
- Brock A, Krause S, Li H, Kowalski M, Goldberg MS, Collins JJ, et al. Silencing HoxA1 by Intraductal Injection of siRNA Lipidoid Nanoparticles Prevents Mammary Tumor Progression in Mice. *Sci Transl Med* (2014) 6(217):217ra2. doi: 10.1126/scitranslmed.3007048
- Zhang X, Emerald BS, Mukhina S, Mohankumar KM, Kraemer A, Yap AS, et al. HOXA1 Is Required for E-Cadherin-Dependent Anchorage-Independent Survival of Human Mammary Carcinoma Cells. *J Biol Chem* (2006) 281(10):6471–81. doi: 10.1074/jbc.M512666200
- Mohankumar KM, Xu XQ, Zhu T, Kannan N, Miller LD, Liu ET, et al. HOXA1-Stimulated Oncogenicity Is Mediated by Selective Upregulation of Components of the P44/42 MAP Kinase Pathway in Human Mammary Carcinoma Cells. *Oncogene* (2007) 26(27):3998–4008. doi: 10.1038/sj.onc.1210180
- Mohankumar KM, Perry JK, Kannan N, Kohno K, Gluckman PD, Emerald BS, et al. Transcriptional Activation of Signal Transducer and Activator of Transcription (STAT) 3 and STAT5B Partially Mediate Homeobox A1-Stimulated Oncogenic Transformation of the Immortalized Human Mammary Epithelial Cell. *Endocrinology* (2008) 149(5):2219–29. doi: 10.1210/en.2007-1320
- Perillo B, Sasso A, Abbondanza C, Palumbo G. 17beta-Estradiol Inhibits Apoptosis in MCF-7 Cells, Inducing Bcl-2 Expression via Two Estrogen-Responsive Elements Present in the Coding Sequence. *Mol Cell Biol* (2000) 20(8):2890–901. doi: 10.1128/MCB.20.8.2890-2901.2000
- Remacle S, Abbas L, De Backer O, Pacico N, Gavalas A, Gofflot F, et al. Loss of Function But No Gain of Function Caused by Amino Acid Substitutions in the

- Hexapeptide of Hoxa1 In Vivo. *Mol Cell Biol* (2004) 24(19):8567–75. doi: 10.1128/MCB.24.19.8567-8575.2004
29. Delval S, Taminiau A, Lamy J, Lallemand C, Gilles C, Noel A, et al. The Pbx Interaction Motif of Hoxa1 Is Essential for Its Oncogenic Activity. *PLoS One* (2011) 6(9):e25247. doi: 10.1371/journal.pone.0025247
 30. Chen J, Rulley HE. An Enhancer Element in the EphA2 (Eck) Gene Sufficient for Rhombomere-Specific Expression Is Activated by HOXA1 and HOXB1 Homeobox Proteins. *J Biol Chem* (1998) 273(38):24670–5. doi: 10.1074/jbc.273.38.24670
 31. Tsouko E, Wang J, Frigo DE, Aydogdu E, Williams C. miR-200a Inhibits Migration of Triple-Negative Breast Cancer Cells Through Direct Repression of the EPHA2 Oncogene. *Carcinogenesis* (2015) 36(9):1051–60. doi: 10.1093/carcin/bgv087
 32. Taminiau A, Draime A, Tys J, Lambert B, Vandeputte J, Nguyen N, et al. HOXA1 Binds RBCK1/HOIL-1 and TRAF2 and Modulates the TNF/NF-kappaB Pathway in a Transcription-Independent Manner. *Nucleic Acids Res* (2016) 44(15):7331–49. doi: 10.1093/nar/gkw606
 33. Lambert B, Vandeputte J, Remacle S, Bergiers I, Simonis N, Twizere JC, et al. Protein Interactions of the Transcription Factor Hoxa1. *BMC Dev Biol* (2012) 12:29. doi: 10.1186/1471-213X-12-29
 34. Fusella F, Seclì L, Busso E, Krepelova A, Moiso E, Rocca S, et al. The IKK/NF-kappaB Signaling Pathway Requires Morgana to Drive Breast Cancer Metastasis. *Nat Commun* (2017) 8(1):1636. doi: 10.1038/s41467-017-01829-1
 35. Soleimani A, Rahmani F, Ferns GA, Ryzhikov M, Avan A, Hassanian SM, et al. Role of the NF-kappaB Signaling Pathway in the Pathogenesis of Colorectal Cancer. *Gene* (2020) 726:144132. doi: 10.1016/j.gene.2019.144132
 36. Revet I, Huizenga G, Koster J, Volckmann R, van Sluis P, Versteeg R, et al. MSX1 Induces the Wnt Pathway Antagonist Genes DKK1, DKK2, DKK3, and SFRP1 in Neuroblastoma Cells, But Does Not Block Wnt3 and Wnt5A Signalling to DVL3. *Cancer Lett* (2010) 289(2):195–207. doi: 10.1016/j.canlet.2009.08.019
 37. Bewick V, Cheek L, Ball J. Statistics Review 12: Survival Analysis. *Crit Care* (2004) 8(5):389–94. doi: 10.1186/cc2955
 38. Matis C, Chomez P, Picard J, Rezsóhazy R. Differential and Opposed Transcriptional Effects of Protein Fusions Containing the VP16 Activation Domain. *FEBS Lett* (2001) 499(1-2):92–6. doi: 10.1016/S0014-5793(01)02532-7
 39. Goudet G, Delhalle S, Biemar F, Martial JA, Peers B. Functional and Cooperative Interactions Between the Homeodomain PDX1, Pbx, and Prep1 Factors on the Somatostatin Promoter. *J Biol Chem* (1999) 274(7):4067–73. doi: 10.1074/jbc.274.7.4067
 40. Remacle S, Shaw-Jackson C, Matis C, Lampe X, Picard J, Rezsóhazy R. Changing Homeodomain Residues 2 and 3 of Hoxa1 Alters its Activity in a Cell-Type and Enhancer Dependent Manner. *Nucleic Acids Res* (2002) 30(12):2663–8. doi: 10.1093/nar/gkf372
 41. Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ, et al. Aberrant Eukaryotic Translation Initiation Factor 4E-Dependent mRNA Transport Impedes Hematopoietic Differentiation and Contributes to Leukemogenesis. *Mol Cell Biol* (2003) 23(24):8992–9002. doi: 10.1128/MCB.23.24.8992-9002.2003
 42. Draime A, Bridoux L, Belpaire M, Pringels T, Tys J, Rezsóhazy R. PRDM14, a Putative Histone Methyl-Transferase, Interacts With and Decreases the Stability and Activity of the HOXA1 Transcription Factor. *Biochim Biophys Acta Gene Regul Mech* (2018) 1861(5):534–42. doi: 10.1016/j.bbagr.2018.02.005
 43. Gionet N, Jansson D, Mader S, Pratt MA. NF-kappaB and Estrogen Receptor Alpha Interactions: Differential Function in Estrogen Receptor-Negative and -Positive Hormone-Independent Breast Cancer Cells. *J Cell Biochem* (2009) 107(3):448–59. doi: 10.1002/jcb.22141
 44. Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest Package: Tests in Linear Mixed Effects Models. *J Stat Software* (2017) 82(13). doi: 10.18637/jss.v082.i13
 45. Shaffer JP. Multiple Hypothesis Testing. *Annu Rev Psychol* (1995) 46:561–84. doi: 10.1146/annurev.ps.46.020195.003021
 46. Hudry B, Remacle S, Delfini MC, Rezsóhazy R, Graba Y, Merabet S. Hox Proteins Display a Common and Ancestral Ability to Diversify Their Interaction Mode With the PBC Class Cofactors. *PLoS Biol* (2012) 10(6):e1001351. doi: 10.1371/journal.pbio.1001351
 47. Magnani L, Ballantyne EB, Zhang X, Lupien M. PBX1 Genomic Pioneer Function Drives ERalpha Signaling Underlying Progression in Breast Cancer. *PLoS Genet* (2011) 7(11):e1002368. doi: 10.1371/journal.pgen.1002368
 48. Berthelsen J, Zappavigna V, Ferretti E, Mavilio F, Blasi F. The Novel Homeoprotein Prep1 Modulates Pbx-Hox Protein Cooperativity. *EMBO J* (1998) 17(5):1434–45. doi: 10.1093/emboj/17.5.1434
 49. Bergiers I, Bridoux L, Nguyen N, Twizere JC, Rezsóhazy R. The Homeodomain Transcription Factor Hoxa2 Interacts With and Promotes the Proteasomal Degradation of the E3 Ubiquitin Protein Ligase RCHY1. *PLoS One* (2013) 8(11):e80387. doi: 10.1371/journal.pone.0080387
 50. Bridoux L, Bergiers I, Draime A, Halbout M, Deneyer N, Twizere JC, et al. KPC2 Relocalizes HOXA2 to the Cytoplasm and Decreases Its Transcriptional Activity. *Biochim Biophys Acta* (2015) 1849(10):1298–311. doi: 10.1016/j.bbagr.2015.08.006
 51. Jin K, Park S, Teo WW, Korangath P, Cho SS, Yoshida T, et al. HOXB7 Is an ERalpha Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance. *Cancer Discovery* (2015) 5(9):944–59. doi: 10.1158/2159-8290.CD-15-0090
 52. Lampe X, Samad OA, Guiguen A, Matis C, Remacle S, Picard JJ, et al. An Ultraconserved Hox-Pbx Responsive Element Resides in the Coding Sequence of Hoxa2 and Is Active in Rhombomere 4. *Nucleic Acids Res* (2008) 36(10):3214–25. doi: 10.1093/nar/gkn148
 53. Lambert B, Vandeputte J, Desmet PM, Hallet B, Remacle S, Rezsóhazy R. Pentapeptide Insertion Mutagenesis of the Hoxa1 Protein: Mapping of Transcription Activation and DNA-Binding Regulatory Domains. *J Cell Biochem* (2010) 110(2):484–96. doi: 10.1002/jcb.22563
 54. Biswas DK, Singh S, Shi Q, Pardee AB, Iglehart JD. Crossroads of Estrogen Receptor and NF-kappaB Signaling. *Sci STKE* (2005) 2005(288):pe27. doi: 10.1126/stke.2882005pe27
 55. Kalaitzidis D, Gilmore TD. Transcription Factor Cross-Talk: The Estrogen Receptor and NF-kappaB. *Trends Endocrinol Metab* (2005) 16(2):46–52. doi: 10.1016/j.tem.2005.01.004
 56. Cunningham MA, Wirth JR, Naga O, Eudaly J, Gilkeson GS, et al. Estrogen Receptor Alpha Binding to ERE Is Required for Full Tlr7- and Tlr9-Induced Inflammation. *SOJ Immunol* (2014) 2(1). doi: 10.15226/soji.2014.00107
 57. Brockman JA, Scher DC, McKinsey JA, Hall TA, Qi SM, Lee X, et al. Coupling of a Signal Response Domain in I Kappa B Alpha to Multiple Pathways for NF-Kappa B Activation. *Mol Cell Biol* (1995) 15(5):2809–18. doi: 10.1128/MCB.15.5.2809
 58. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-kappaB. *Science* (1996) 274(5288):784–7. doi: 10.1126/science.274.5288.784
 59. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 Overexpression Causes Tumorigenesis of Mammary Epithelial Cells. *Cancer Res* (2001) 61(5):2301–6.
 60. Zelinski DP, Zantek ND, Walker-Daniels J, Peters MA, Taparowsky EJ, Kinch MS. Estrogen and Myc Negatively Regulate Expression of the EphA2 Tyrosine Kinase. *J Cell Biochem* (2002) 85(4):714–20. doi: 10.1002/jcb.10186
 61. Nikas I, Ryu HS, Theocharis S. Viewing the Eph Receptors With a Focus on Breast Cancer Heterogeneity. *Cancer Lett* (2018) 434:160–71. doi: 10.1016/j.canlet.2018.07.030
 62. Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V, et al. MicroRNA-30c Expression Level is an Independent Predictor of Clinical Benefit of Endocrine Therapy in Advanced Estrogen Receptor Positive Breast Cancer. *Breast Cancer Res Treat* (2011) 127(1):43–51. doi: 10.1007/s10549-010-0940-x
 63. Chen D, Sun Y, Yuan Y, Han Z, Zhang P, Zhang J, et al. miR-100 Induces Epithelial-Mesenchymal Transition But Suppresses Tumorigenesis, Migration and Invasion. *PLoS Genet* (2014) 10(2):e1004177. doi: 10.1371/journal.pgen.1004177
 64. Wang X, Li Y, Qi W, Zhang N, Sun M, Huo Q, et al. MicroRNA-99a Inhibits Tumor Aggressive Phenotypes Through Regulating HOXA1 in Breast Cancer Cells. *Oncotarget* (2015) 6(32):32737–47. doi: 10.18632/oncotarget.5355
 65. Ni LY, Zhao JD, Lu YH, Li W, Li BL, Wang XC, et al. MicroRNA-30c Suppressed Giant-Cell Tumor of Bone Cell Metastasis and Growth via Targeting HOXA1. *Eur Rev Med Pharmacol Sci* (2017) 21(21):4819–27.
 66. Zhang Y, Fang J, Zhao H, Yu Y, Cao X, Zhang B, et al. Downregulation of microRNA-1469 Promotes the Development of Breast Cancer via Targeting HOXA1 and Activating PTEN/PI3K/AKT and Wnt/beta-Catenin Pathways. *J Cell Biochem* (2019) 120(4):5097–107. doi: 10.1002/jcb.27786
 67. Mahajan K, Lawrence HR, Lawrence NJ, Mahajan NP. ACK1 Tyrosine Kinase Interacts With Histone Demethylase KDM3A to Regulate the Mammary Tumor Oncogene HOXA1. *J Biol Chem* (2014) 289(41):28179–91. doi: 10.1074/jbc.M114.584425

68. Yamaguchi N, Ito T, Azuma S, Ito E, Honma R, Yanagisawa Y, et al. Constitutive Activation of Nuclear Factor-kappaB Is Preferentially Involved in the Proliferation of Basal-Like Subtype Breast Cancer Cell Lines. *Cancer Sci* (2009) 100(9):1668–74. doi: 10.1111/j.1349-7006.2009.01228.x
69. Zhou Y, Eppenberger-Castori S, Marx C, Yau C, Scott GK, Eppenberger U, et al. Activation of Nuclear Factor-kappaB (NFkappaB) Identifies a High-Risk Subset of Hormone-Dependent Breast Cancers. *Int J Biochem Cell Biol* (2005) 37(5):1130–44. doi: 10.1016/j.biocel.2004.09.006
70. Sas L, Lardon F, Vermeulen PB, Hauspy J, Van Dam P, Pauwels P, et al. The Interaction Between ER and NFkappaB in Resistance to Endocrine Therapy. *Breast Cancer Res* (2012) 14(4):212. doi: 10.1186/bcr3196
71. Yde CW, Emdal KB, Guerra B, Lykkesfeldt AE. NFkappaB Signaling is Important for Growth of Antiestrogen Resistant Breast Cancer Cells. *Breast Cancer Res Treat* (2012) 135(1):67–78. doi: 10.1007/s10549-012-2053-1
72. Belguise K, Sonenshein GE. PKCtheta Promotes C-Rel-Driven Mammary Tumorigenesis in Mice and Humans by Repressing Estrogen Receptor Alpha Synthesis. *J Clin Invest* (2007) 117(12):4009–21. doi: 10.1172/JCI32424
73. Wang X, Belguise K, O'Neill CF, Sanchez-Morgan N, Romagnoli M, Eddy SF, et al. RelB NF-kappaB Represses Estrogen Receptor Alpha Expression via Induction of the Zinc Finger Protein Blimp1. *Mol Cell Biol* (2009) 29(14):3832–44. doi: 10.1128/MCB.00032-09
74. Reijm EA, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, van Gelder ME, et al. Decreased Expression of EZH2 Is Associated With Upregulation of ER and Favorable Outcome to Tamoxifen in Advanced Breast Cancer. *Breast Cancer Res Treat* (2011) 125(2):387–94. doi: 10.1007/s10549-010-0836-9
75. Khongthong P, Roseweir AK, Edwards J. The NF-KB Pathway and Endocrine Therapy Resistance in Breast Cancer. *Endocr Relat Cancer* (2019) 26(6):R369–80. doi: 10.1530/ERC-19-0087
76. Oida K, Matsuda A, Jung K, Xia Y, Jang H, Amagai Y, et al. Nuclear factor-kB Plays a Critical Role in Both Intrinsic and Acquired Resistance Against Endocrine Therapy in Human Breast Cancer Cells. *Sci Rep* (2014) 4:4057. doi: 10.1038/srep04057
77. Draime A, Bridoux L, Belpaire M, Pringels T, Degand H, Morsomme P, et al. The O-GlcNAc Transferase OGT Interacts With and Post-Translationally Modifies the Transcription Factor HOXA1. *FEBS Lett* (2018) 592(7):1185–201. doi: 10.1002/1873-3468.13015
78. Jin K, Kong X, Shah T, Penet MF, Wildes F, Sgroi DC, et al. The HOXB7 Protein Renders Breast Cancer Cells Resistant to Tamoxifen Through Activation of the EGFR Pathway. *Proc Natl Acad Sci USA* (2012) 109(8):2736–41. doi: 10.1073/pnas.1018859108
79. Shah N, Jin K, Cruz LA, Park S, Sadik H, Cho S, et al. HOXB13 Mediates Tamoxifen Resistance and Invasiveness in Human Breast Cancer by Suppressing ERalpha and Inducing IL-6 Expression. *Cancer Res* (2013) 73(17):5449–58. doi: 10.1158/0008-5472.CAN-13-1178
80. Jin K, Sukumar S. HOX Genes: Major Actors in Resistance to Selective Endocrine Response Modifiers. *Biochim Biophys Acta* (2016) 1865(2):105–10. doi: 10.1016/j.bbcan.2016.01.003

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Belpaire, Ewbank, Taminiau, Bridoux, Deneyer, Marchese, Lima-Mendez, Baurain, Geerts and Rezhohazy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.